Call Us Today @ 0172 - 4680800 | info@indswift.com | NSE - BSE
Oncolytics Biotech initiates phase 2 study combining Pelareorep and Keytruda in advanced pancreatic cancer
 
Oncolytics Biotech Inc currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, has announced that the first patient was treated in a phase 2 study combining pelareorep with Merck's Keytruda to treat advanced pancreatic adenocarcinoma. The primary objective of the study is to determine the overall response rate (ORR) by iRECIST criteria. Secondary objectives include safety of the combination, immune response as determined by analysis of pre- and post-treatment biopsies and blood-based immune markers, determination of progression-free survival (PFS) by iRECIST criteria; and one-year, two-year and median overall survival (OS).

"We are very excited to start enrollment in this combination study which expands upon our findings from an earlier Keytruda study in advanced pancreatic cancer," said Dr Matt Coffey, president and chief executive officer of Oncolytics Biotech. "REO 024, our previous phase 1b study with Keytruda, showed objective response, long-term stabilization of disease and promotion of an inflamed phenotype in second line pancreatic cancer patients. This new phase two study should corroborate anti-tumor activity and potentially confirm predictive biomarkers laying the groundwork towards our goal of becoming a standardized backbone for checkpoint inhibitors."

This study is a phase 2, single arm, open-label study enrolling up to 30 patients with advanced pancreatic adenocarcinoma who experienced disease progression or did not tolerate first-line therapy. The principal investigator is Dr Devalingham Mahalingam, of Northwestern University. The first 16 patients will be enrolled in stage one, and up to 14 additional patients will be enrolled in stage two if pre-specified criteria are met. The pre-defined criteria state that, for the primary objective, three or more responses out of 16 are needed in stage one to continue the trial to the full 30 patients.

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development programme emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses.

(Pharmabiz.com)
 
Other Related News:
Beware of evening stress
Severe shortage of antibiotic eye drops & vitamin C tablets across India as these products brought under price control
Oncolytics Biotech initiates phase 2 study combining Pelareorep and Keytruda in advanced pancreatic cancer
NIH scientists illuminate causes of hepatitis b virus-associated acute liver failure
Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics : EMA
CHMP recommends first oral-only treatment for sleeping sickness
Both Bacteria and Viruses Can Cause Pneumonia, But One Is Much Worse for the Heart
Lenvima backed for NHS use to treat liver cancer
Drug overdose epidemic goes far beyond opioids, requires new policies
Drug for pancreatic cancer developed by college of pharmacy researchers